Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase
inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3 trail is studying the
efficacy and safety of Tucidinostat, in Combination with Rituximab, Cyclophosphamide,
Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed MYC/BCL2
Double-Expressor Diffuse Large B-cell Lymphoma.